Who
Peter C. Brandt
Director
Company insider
Files Form 4 as: Director, IN8bio; Director, Opus Genetics; Director, Auxilium Pharmaceuticals; CEO, Epocrates; President and CEO, Noven Pharmaceuticals.
In numbers
- Trades disclosed
- 109
- Buys
- 11
- Sells
- 0
- Bought
- $1.3M
- Sold
- $0
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 29 Apr 2008
- Last trade
- 9 May 2026
- Last filed
- 12 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 May 2026filed 12 May 2026 | INAB IN8biooption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 9 May 2026filed 12 May 2026 | INAB IN8biooption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 22 Dec 2025filed 23 Dec 2025 | INAB IN8bioBiotechnology | SEC FORM 4 Code A | $100K72,464 at $1.38 | filing |
| 8 May 2025filed 12 May 2025 | INAB IN8biooption or derivative · Biotechnology | SEC FORM 4 Code A | —63,150 at $0.00 | filing |
| 30 Apr 2025filed 7 May 2025 | INAB IN8biooption or derivative · Biotechnology | SEC FORM 4 Code M | —81,967 at $0.00 | filing |
| 30 Apr 2025filed 7 May 2025 | INAB IN8biooption or derivative · Biotechnology | SEC FORM 4 Code M | —81,967 at $0.00 | filing |
| 30 Apr 2025filed 7 May 2025 | INAB IN8bioBiotechnology | SEC FORM 4 Code M | $15K81,967 at $0.18 | filing |
| 30 Apr 2025filed 7 May 2025 | INAB IN8bioBiotechnology | SEC FORM 4 Code M | $15K81,967 at $0.18 | filing |
| 27 Apr 2025filed 7 May 2025 | INAB IN8biooption or derivative · Biotechnology | SEC FORM 4 Code D | —81,967 | filing |
| 27 Apr 2025filed 7 May 2025 | INAB IN8biooption or derivative · Biotechnology | SEC FORM 4 Code A | —81,967 | filing |
| 27 Apr 2025filed 7 May 2025 | INAB IN8biooption or derivative · Biotechnology | SEC FORM 4 Code D | —81,967 | filing |
| 27 Apr 2025filed 7 May 2025 | INAB IN8biooption or derivative · Biotechnology | SEC FORM 4 Code A | —81,967 | filing |
| 19 Dec 2024filed 23 Dec 2024 | INAB IN8biooption or derivative · Biotechnology | SEC FORM 4 Code A | —49,490 at $0.00 | filing |
| 4 Oct 2024filed 8 Oct 2024 | INAB IN8biooption or derivative · Biotechnology | SEC FORM 4 Code D | —81,967 | filing |
| 4 Oct 2024filed 8 Oct 2024 | INAB IN8biooption or derivative · Biotechnology | SEC FORM 4 Code A | —81,967 | filing |
| 4 Oct 2024filed 8 Oct 2024 | INAB IN8biooption or derivative · Biotechnology | SEC FORM 4 Code A | —253,164 | filing |
| 4 Oct 2024filed 8 Oct 2024 | INAB IN8bioBiotechnology | SEC FORM 4 Code A | —253,164 | filing |
| 12 Jun 2024filed 14 Jun 2024 | INAB IN8biooption or derivative · Biotechnology | SEC FORM 4 Code A | —33,650 at $0.00 | filing |
| 13 Dec 2023filed 15 Dec 2023 | INAB IN8biooption or derivative · Biotechnology | SEC FORM 4 Code A | —81,967 | filing |
| 13 Dec 2023filed 15 Dec 2023 | INAB IN8biooption or derivative · Biotechnology | SEC FORM 4 Code A | —81,967 | filing |
News
Opus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood BlindnessIRD · manilatimes.net · 21 Oct 2026Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of PresbyopiaIRD · manilatimes.net · 16 Oct 2026Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026IRD · manilatimes.net · 15 Oct 2026
0 headlines in the last 90 days name Peter C. Brandt; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.